Nitric oxide: A key mediator of biofilm dispersal with applications in infectious diseases

Current Pharmaceutical Design

Volumn 21, Issue 1, 2015, Pages 31-42

  Barraud, Nicolas ^a   Kelso, Michael J ^b   Rice, Scott A ^a,c   Kjelleberg, Staffan ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Biofilms; Cystic fibrosis; Dispersal; Nitric oxide; Pseudomonas aeruginosa; Surface coatings; Targeted delivery

Indexed keywords

ANTIBIOTIC AGENT; ARGININE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CYCLIC GMP; DODECYL SULFATE SODIUM; DRINKING WATER; GLYCERYL TRINITRATE; HYDROGEN PEROXIDE; NANOPARTICLE; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE REDUCTASE; NITRITE; NITRITE REDUCTASE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE; POLYMER; PRODRUG; REACTIVE NITROGEN SPECIES; S NITROSOGLUTATHIONE; SCAVENGER; TOBRAMYCIN;

ALIIVIBRIO FISCHERI; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; AZOSPIRILLUM BRASILENSE; BACILLUS LICHENIFORMIS; BACILLUS SUBTILIS; BIOFILM; CANDIDA ALBICANS; CANDIDA TROPICALIS; CATHETER; CELL DEATH; CONTACT LENS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; ENDOPROSTHESIS; ESCHERICHIA COLI; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUSOBACTERIUM NUCLEATUM; HELICOBACTER PYLORI; HUMAN; INFECTION; INFECTION CONTROL; INFLAMMATION; LEGIONELLA PNEUMOPHILA; LUNG FIBROSIS; NEISSERIA GONORRHOEAE; NITROSATIVE STRESS; NITROSOMONAS EUROPAEA; NONHUMAN; PATHOGENESIS; PROTEIN PROCESSING; PSEUDOALTEROMONAS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PUTIDA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; SERRATIA MARCESCENS; SHEWANELLA; SHEWANELLA ONEIDENSIS; STAPHYLOCOCCUS AUREUS; SURFACE PROPERTY; SYSTEMIC THERAPY; TISSUE SPECIFICITY; ULTRAVIOLET RADIATION; ULVA; VIBRIO CHOLERAE; WATER SUPPLY; BACTERIAL INFECTIONS; DOSE RESPONSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BACTERIAL INFECTIONS; BIOFILMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 84919781393     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140905112822     Document Type: Article

References (159)

1. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-8.
2. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
3. Buckingham-Meyer K, Goeres DM, Hamilton MA. Comparative evaluation of biofilm disinfectant efficacy tests. J Microbiol Methods 2007; 70: 236-44.
4. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2: 95-108.
5. Mulcahy H, Charron-Mazenod L, Lewenza S. Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog 2008; 4: e1000213.
6. Giwercman B, Jensen ET, Hoiby N, et al. Induction of betalactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother 1991; 35: 1008-10.
7. Leid JG, Willson CJ, Shirtliff ME, et al. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing. J Immunol 2005; 175: 7512-8.
8. Mah TF, Pitts B, Pellock B, et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426: 306-10.
9. Hassett DJ, Ma JF, Elkins JG, et al. Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol 1999; 34: 1082-93.
10. Hoiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35: 322-32.
11. Roberts AP, Mullany P. Oral biofilms: a reservoir of transferable, bacterial, antimicrobial resistance. Expert Rev Anti-Infect Ther 2010; 8: 1441-50.
12. Bagge N, Hentzer M, Andersen JB, et al. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2004; 48: 1168-74.
13. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007; 5: 48-56.
14. Kaplan JB. Antibiotic-induced biofilm formation. Int J Artif Organs 2011; 34: 737-51.
15. McDougald D, Rice SA, Barraud N, et al. Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal. Nat Rev Microbiol 2012; 10: 39-50.
16. Webb JS, Thompson LS, James S, et al. Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol 2003; 185: 4585-92.
17. Mai-Prochnow A, Ferrari BC, Webb JS, et al. Ecological advantages of autolysis during the development and dispersal of Pseudoalteromonas tunicata biofilms. Appl Environ Microbiol 2006; 72: 5414-20.
18. Sauer K, Cullen MC, Rickard AH, et al. Characterization of nutrient-induced dispersion in Pseudomonas aeruginosa PAO1 biofilm. J Bacteriol 2004; 186: 7312-26.
19. Gjermansen M, Ragas P, Sternberg C, et al. Characterization of starvation-induced dispersion in Pseudomonas putida biofilms. Environ Microbiol 2005; 7: 894-906.
20. Schleheck D, Barraud N, Klebensberger J, et al. Pseudomonas aeruginosa PAO1 preferentially grows as aggregates in liquid batch cultures and disperses upon starvation. PLoS One 2009; 4: e5513.
21. Thormann KM, Saville RM, Shukla S, et al. Induction of rapid detachment in Shewanella oneidensis MR-1 biofilms. J Bacteriol 2005; 187: 1014-21.
22. Barraud N, Hassett DJ, Hwang SH, et al. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006; 188: 7344-53.
23. Barraud N, Storey MV, Moore ZP, et al. Nitric oxide-mediated dispersal in single-and multi-species biofilms of clinically and industrially relevant microorganisms. Microb Biotechnol 2009; 2: 370-8.
24. Liu N, Xu Y, Hossain S, et al. Nitric oxide regulation of cyclic di-GMP synthesis and hydrolysis in Shewanella woodyi. Biochemistry 2012; 51: 2087-99.
25. Musk DJ, Banko DA, Hergenrother PJ. Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa. Chem Biol 2005; 12: 789-96.
26. Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72: 2064-9.
27. Kolodkin-Gal I, Romero D, Cao S, et al. D-amino acids trigger biofilm disassembly. Science 2010; 328: 627-9.
28. Rice SA, Koh KS, Queck SY, et al. Biofilm formation and sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. J Bacteriol 2005; 187: 3477-85.
29. Boles BR, Horswill AR. agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog 2008; 4: e1000052.
30. Dow JM, Crossman L, Findlay K, et al. Biofilm dispersal in Xanthomonas campestris is controlled by cell-cell signaling and is required for full virulence to plants. Proc Natl Acad Sci USA 2003; 100: 10995-1000.
31. Davies DG, Marques CN. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J Bacteriol 2009; 191: 1393-403.
32. Römling U, Galperin MY, Gomelsky M. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev 2013; 77: 1-52.
33. Huynh TT, McDougald D, Klebensberger J, et al. Glucose starvation-induced dispersal of Pseudomonas aeruginosa biofilms is cAMP and energy dependent. PLoS One 2012; 7: e42874.
34. Kalivoda EJ, Brothers KM, Stella NA, et al. Bacterial cyclic AMPphosphodiesterase activity coordinates biofilm formation. PLoS One 2013; 8: e71267.
35. Kaplan JB, Ragunath C, Velliyagounder K, et al. Enzymatic detachment of Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2004; 48: 2633-6.
36. Kuiper I, Lagendijk EL, Pickford R, et al. Characterization of two Pseudomonas putida lipopeptide biosurfactants, putisolvin I and II, which inhibit biofilm formation and break down existing biofilms. Mol Microbiol 2004; 51: 97-113.
37. Schooling SR, Charaf UK, Allison DG, et al. A role for rhamnolipid in biofilm dispersion. Biofilms 2004; 1: 91-9.
38. Sauer K, Camper AK, Ehrlich GD, et al. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 184: 1140-54.
39. Barraud N, Schleheck D, Klebensberger J, et al. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol 2009; 191: 7333-42.
40. Rogers SA, Huigens RW, 3rd, Cavanagh J, et al. Synergistic effects between conventional antibiotics and 2-aminoimidazolederived antibiofilm agents. Antimicrob Agents Chemother 2010; 54: 2112-8.
41. Frei R, Breitbach AS, Blackwell HE. 2-Aminobenzimidazole derivatives strongly inhibit and disperse Pseudomonas aeruginosa biofilms. Angew Chem-Int Edit 2012; 51: 5226-9.
42. Byrd MS, Pang B, Hong W, et al. Direct evaluation of Pseudomonas aeruginosa biofilm mediators in a chronic infection model. Infect Immun 2011; 79: 3087-95.
43. Christensen LD, van Gennip M, Rybtke MT, et al. Clearance of Pseudomonas aeruginosa foreign-body biofilm infections through reduction of the cyclic di-GMP level in the bacteria. Infect Immun 2013; 81: 2705-13.
44. Ma Q, Yang Z, Pu M, et al. Engineering a novel c-di-GMP-binding protein for biofilm dispersal. Environ Microbiol 2011; 13: 631-42.
45. Potter AJ, Kidd SP, Edwards JL, et al. Thioredoxin reductase is essential for protection of Neisseria gonorrhoeae against killing by nitric oxide and for bacterial growth during interaction with cervical epithelial cells. J Infect Dis 2009; 199: 227-35.
46. Werwinski S, Wharton JA, Iglesias-Rodriguez MD, et al. Electrochemical sensing of aerobic marine bacterial biofilms and the influence of nitric oxide attachment control. Mater Res Soc Symp Proc 2011; 1356.
47. Davidson SK, Koropatnick TA, Kossmehl R, et al. NO means 'yes' in the squid-vibrio symbiosis: nitric oxide (NO) during the initial stages of a beneficial association. Cell Microbiol 2004; 6: 1139-51.
48. Schlag S, Nerz C, Birkenstock TA, et al. Inhibition of staphylococcal biofilm formation by nitrite. J Bacteriol 2007; 189: 7911-9.
49. Schreiber F, Beutler M, Enning D, et al. The role of nitric-oxidesynthase-derived nitric oxide in multicellular traits of Bacillus subtilis 3610: biofilm formation, swarming, and dispersal. BMC Microbiol 2011; 11: 111.
50. Carlson HK, Vance RE, Marletta MA. H-NOX regulation of c-di-GMP metabolism and biofilm formation in Legionella pneumophila. Mol Microbiol 2010; 77: 930-42.
51. Schmidt I, Steenbakkers PJ, op den Camp HJ, et al. Physiologic and proteomic evidence for a role of nitric oxide in biofilm formation by Nitrosomonas europaea and other ammonia oxidizers. J Bacteriol 2004; 186: 2781-8.
52. Liu P, Huang Q, Chen W. Heterologous expression of bacterial nitric oxide synthase gene: a potential biological method to control biofilm development in the environment. Can J Microbiol 2012; 58: 336-44.
53. Cathie K, Howlin RP, Sukhtankar P, et al. Low dose nitric oxide as adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Abstract ID Week; 2013; San Francisco, CA.
54. Plate L, Marletta MA. Nitric oxide modulates bacterial biofilm formation through a multicomponent cyclic-di-GMP signaling network. Mol Cell 2012; 46: 449-60.
55. Arruebarrena Di Palma A, Pereyra CM, Moreno Ramirez L, et al. Denitrification-derived nitric oxide modulates biofilm formation in Azospirillum brasilense. FEMS Microbiol Lett 2013; 338: 77-85.
56. Wang Y, Ruby EG. The roles of NO in microbial symbioses. Cell Microbiol 2011; 13: 518-26.
57. Wilken M, Huchzermeyer B. Suppression of mycelia formation by NO produced endogenously in Candida tropicalis. Eur J Cell Biol 1999; 78: 209-13.
58. Tao YP, Misko TP, Howlett AC, et al. Nitric oxide, an endogenous regulator of Dictyostelium discoideum differentiation. Development 1997; 124: 3587-95.
59. Thompson SE, Callow ME, Callow JA. The effects of nitric oxide in settlement and adhesion of zoospores of the green alga Ulva. Biofouling 2010; 26: 167-78.
60. Bishop CD, Brandhorst BP. On nitric oxide signaling, metamorphosis, and the evolution of biphasic life cycles. Evol Dev 2003; 5: 542-50.
61. Sondermann H, Shikuma NJ, Yildiz FH. You've come a long way: c-di-GMP signaling. Curr Opin Microbiol 2012; 15: 140-6.
62. Arora DP, Boon EM. Nitric oxide regulated two-component signaling in Pseudoalteromonas atlantica. Biochem Biophys Res Commun 2012; 421: 521-6.
63. Ho CL, Chong KS, Oppong JA, et al. Visualizing the perturbation of cellular cyclic di-GMP levels in bacterial cells. J Am Chem Soc 2013; 135: 566-9.
64. Partridge JD, Bodenmiller DM, Humphrys MS, et al. NsrR targets in the Escherichia coli genome: new insights into DNA sequence requirements for binding and a role for NsrR in the regulation of motility. Mol Microbiol 2009; 73: 680-94.
65. Roy AB, Petrova OE, Sauer K. The phosphodiesterase DipA (PA5017) is essential for Pseudomonas aeruginosa biofilm dispersion. J Bacteriol 2012; 194: 2904-15.
66. Li Y, Heine S, Entian M, et al. NO-induced biofilm dispersion in Pseudomonas aeruginosa is mediated by an MHYT domaincoupled phosphodiesterase. J Bacteriol 2013; 195: 3531-42.
67. Newell PD, Monds RD, O'Toole GA. LapD is a bis-(3', 5')-cyclic dimeric GMP-binding protein that regulates surface attachment by Pseudomonas fluorescens Pf0-1. Proc Natl Acad Sci USA 2009; 106: 3461-6.
68. Gjermansen M, Nilsson M, Yang L, et al. Characterization of starvation-induced dispersion in Pseudomonas putida biofilms: genetic elements and molecular mechanisms. Mol Microbiol 2010; 75: 815-26.
69. Nioche P, Berka V, Vipond J, et al. Femtomolar sensitivity of a NO sensor from Clostridium botulinum. Science 2004; 306: 1550-3.
70. Plate L, Marletta MA. Nitric oxide-sensing H-NOX proteins govern bacterial communal behavior. Trends Biochem Sci 2013; 38: 566-75.
71. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997; 99: 2818-25.
72. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50.
73. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
74. Taylor BS, Geller DA. Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 2000; 13: 413-24.
75. Maresca M, Miller D, Quitard S, et al. Enteropathogenic Escherichia coli (EPEC) effector-mediated suppression of antimicrobial nitric oxide production in a small intestinal epithelial model system. Cell Microbiol 2005; 7: 1749-62.
76. Chakravortty D, Hansen-Wester I, Hensel M. Salmonella pathogenicity island 2 mediates protection of intracellular Salmonella from reactive nitrogen intermediates. J Exp Med 2002; 195: 1155-66.
77. Gobert AP, McGee DJ, Akhtar M, et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc Natl Acad Sci USA 2001; 98: 13844-9.
78. Carossa S, Pera P, Doglio P, et al. Oral nitric oxide during plaque deposition. Eur J Clin Invest 2001; 31: 876-9.
79. Zhang Y, Li X, Carpinteiro A, et al. Kinase suppressor of Ras-1 protects against pulmonary Pseudomonas aeruginosa infections. Nat Med 2011; 17: 341-6.
80. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102: 1200-7.
81. de Winter-de Groot KM, van der Ent CK. Nitric oxide in cystic fibrosis. J Cyst Fibros 2005; 4 (Suppl 2): 25-9.
82. Meng QH, Springall DR, Bishop AE, et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998; 184: 323-31.
83. Moeller A, Horak F, Jr., Lane C, et al. Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis. Thorax 2006; 61: 514-20.
84. Grasemann H, Storm van's Gravesande K, Buscher R, et al. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167: 390-4.
85. Grasemann H, Schwiertz R, Matthiesen S, et al. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005; 172: 1523-8.
86. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003; 4: 8.
87. Darling KE, Evans TJ. Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis. Infect Immun 2003; 71: 2341-9.
88. Seimetz M, Parajuli N, Pichl A, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147: 293-305.
89. Peng HB, Spiecker M, Liao JK. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol 1998; 161: 1970-6.
90. Mishra BB, Rathinam VA, Martens GW, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 2013; 14: 52-60.
91. Niedbala W, Cai B, Liu H, et al. Nitric oxide induces CD4+CD25+ Foxp3-regulatory T cells from CD4+CD25-T cells via p53, IL-2, and OX40. Proc Natl Acad Sci USA 2007; 104: 15478-83.
92. Poschet JF, Fazio JA, Timmins GS, et al. Endosomal hyperacidification in cystic fibrosis is due to defective nitric oxide-cylic GMP signalling cascade. EMBO Rep 2006; 7: 553-9.
93. Lundberg JO, Lundberg JM, Alving K, et al. Nitric oxide and inflammation: the answer is blowing in the wind. Nat Med 1997; 3: 30-1.
94. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352: 2163-73.
95. Barraud N, Kardak BG, Yepuri NR, et al. Cephalosporin-3'-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. Angew Chem-Int Edit 2012; 51: 9057-60.
96. Ridnour LA, Thomas DD, Mancardi D, et al. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem 2004; 385: 1-10.
97. Ghaffari A, Miller CC, McMullin B, et al. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide 2006; 14: 21-9.
98. Miller CC, Hergott CA, Rohan M, et al. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibros 2013.
99. Shekhter AB, Serezhenkov VA, Rudenko TG, et al. Beneficial effect of gaseous nitric oxide on the healing of skin wounds. Nitric Oxide 2005; 12: 210-9.
100. Sulemankhil I, Ganopolsky JG, Dieni CA, et al. Prevention and treatment of virulent bacterial biofilms with an enzymatic nitric oxide-releasing dressing. Antimicrob Agents Chemother 2012; 56: 6095-103.
101. Carlsson S, Wiklund NP, Engstrand L, et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001; 5: 580-6.
102. Carlsson S, Weitzberg E, Wiklund P, et al. Intravesical nitric oxide delivery for prevention of catheter-associated urinary tract infections. Antimicrob Agents Chemother 2005; 49: 2352-5.
103. Regev-Shoshani G, Ko M, Miller C, et al. Slow release of nitric oxide from charged catheters and its effect on biofilm formation by Escherichia coli. Antimicrob Agents Chemother 2010; 54: 273-9.
104. Babaei S, Teichert-Kuliszewska K, Monge JC, et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998; 82: 1007-15.
105. Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006; 23: 594-608.
106. Cooney RV, Mordan LJ. Cellular nitrogen oxide production: Its role in endogeneous mutation and carcinogenesis. In: Cutler RG, Packer L, Bertram J, Mori A, Eds. Oxidative Stress and Aging: Birkhäuser Basel 1995: pp. 45-52.
107. Ricciardolo FL, Sterk PJ, Gaston B, et al. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004; 84: 731-65.
108. Miller C, Miller M, McMullin B, et al. A phase I clinical study of inhaled nitric oxide in healthy adults. J Cyst Fibros 2012; 11: 324-31.
109. Miller C. Inhaled nitric oxide. Proceedings of the 36th European Cystic Fibrosis Conference; 2013 June 12-15; Lisbon, Portugal. http://www. hopkinscme. net/ofp/eCysticFibrosisReview/newsletters/2013/0913. html.
110. Gusarov I, Nudler E. NO-mediated cytoprotection: instant adaptation to oxidative stress in bacteria. Proc Natl Acad Sci USA 2005; 102: 13855-60.
111. Husain M, Bourret TJ, McCollister BD, et al. Nitric oxide evokes an adaptive response to oxidative stress by arresting respiration. J Biol Chem 2008; 283: 7682-9.
112. McCollister BD, Hoffman M, Husain M, et al. Nitric oxide protects bacteria from aminoglycosides by blocking the energy-dependent phases of drug uptake. Antimicrob Agents Chemother 2011; 55: 2189-96.
113. Gusarov I, Shatalin K, Starodubtseva M, et al. Endogenous nitric oxide protects bacteria against a wide spectrum of antibiotics. Science 2009; 325: 1380-4.
114. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-902.
115. Miller CC, Miller MK, Ghaffari A, et al. Treatment of chronic nonhealing leg ulceration with gaseous nitric oxide: a case study. J Cutan Med Surg 2004; 8: 233-8.
116. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353: 2683-95.
117. Bloch KD, Ichinose F, Roberts JD, Jr., et al. Inhaled NO as a therapeutic agent. Cardiovasc Res 2007; 75: 339-48.
118. Webert KE, Vanderzwan J, Duggan M, et al. Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia. Crit Care Med 2000; 28: 2397-405.
119. Jean D, Maitre B, Tankovic J, et al. Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit Care Med 2002; 30: 442-7.
120. Cathie K, Howlin RP, Barraud N, et al. RATNO-Reducing Antibiotic Tolerance using Nitric Oxide in Cystic Fibrosis-A proof of concept study. Abstract ID Week; 2013; San Francisco, CA.
121. Corker H, Poole RK. Nitric oxide formation by Escherichia coli. Dependence on nitrite reductase, the NO-sensing regulator Fnr, and flavohemoglobin Hmp. J Biol Chem 2003; 278: 31584-92.
122. Crane BR, Sudhamsu J, Patel BA. Bacterial nitric oxide synthases. Annu Rev Biochem 2010; 79: 445-70.
123. Borriello G, Richards L, Ehrlich GD, et al. Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother 2006; 50: 382-4.
124. Yoon SS, Coakley R, Lau GW, et al. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest 2006; 116: 436-46.
125. Major TA, Panmanee W, Mortensen JE, et al. Sodium nitritemediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions. Antimicrob Agents Chemother 2010; 54: 4671-7.
126. Grasemann H, Grasemann C, Kurtz F, et al. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 2005; 25: 62-8.
127. Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 208-12.
128. Scatena R, Bottoni P, Martorana GE, et al. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 2005; 14: 835-46.
129. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151: 305-21.
130. Snyder AH, McPherson ME, Hunt JF, et al. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002; 165: 922-6.
131. Que LG, Liu L, Yan Y, et al. Protection from experimental asthma by an endogenous bronchodilator. Science 2005; 308: 1618-21.
132. Keefer LK. Fifty years of diazeniumdiolate research. From laboratory curiosity to broad-spectrum biomedical advances. ACS Chem Biol 2011; 6: 1147-55.
133. de la Fuente-Núñez C, Reffuveille F, Fairfull-Smith KE, et al. The effect of nitroxides on swarming motility and biofilms, multicellular behaviors in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013.
134. Yepuri NR, Barraud N, Shah Mohammadi N, et al. Synthesis of cephalosporin-3'-diazeniumdiolates: biofilm dispersing NO-donor prodrugs activated by lactamase. Chem Commun 2013; 49: 4791-3.
135. Del Rosso JQ. Oral cephalosporin antibiotics: an overview of clinical pharmacology and dermatologic applications. Cutis 2003; 71: 153-7.
136. Rothrock AR, Donkers RL, Schoenfisch MH. Synthesis of nitric oxide-releasing gold nanoparticles. J Am Chem Soc 2005; 127: 9362-3.
137. Hetrick EM, Shin JH, Stasko NA, et al. Bactericidal efficacy of nitric oxide-releasing silica nanoparticles. ACS Nano 2008; 2: 235-46.
138. Carpenter AW, Slomberg DL, Rao KS, et al. Influence of scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles. ACS Nano 2011; 5: 7235-44.
139. Friedman A, Blecher K, Sanchez D, et al. Susceptibility of Grampositive and-negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence 2011; 2: 217-21.
140. Hetrick EM, Shin JH, Paul HS, et al. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 2009; 30: 2782-9.
141. Carpenter AW, Worley BV, Slomberg DL, et al. Dual action antimicrobials: nitric oxide release from quaternary ammoniumfunctionalized silica nanoparticles. Biomacromolecules 2012; 13: 3334-42.
142. Sun B, Slomberg DL, Chudasama SL, et al. Nitric oxide-releasing dendrimers as antibacterial agents. Biomacromolecules 2012; 13: 3343-54.
143. Hentzer M, Givskov M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J Clin Invest 2003; 112: 1300-7.
144. Hassett DJ, Cuppoletti J, Trapnell B, et al. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002; 54: 1425-43.
145. Toyofuku M, Nomura N, Fujii T, et al. Quorum sensing regulates denitrification in Pseudomonas aeruginosa PAO1. J Bacteriol 2007; 189: 4969-72.
146. Hentzer M, Wu H, Andersen JB, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003; 22: 3803-15.
147. Kutty SK, Barraud N, Pham A, et al. Design, synthesis, and evaluation of fimbrolide-nitric oxide donor hybrids as antimicrobial agents. J Med Chem 2013; 56: 9517-29.
148. Keefer LK. Biomaterials: thwarting thrombus. Nat Mater 2003; 2: 357-8.
149. Verma S, Marsden PA. Nitric oxide-eluting polyurethanes-vascular grafts of the future? N Engl J Med 2005; 353: 730-1.
150. Nablo BJ, Schoenfisch MH. Antibacterial properties of nitric oxide-releasing sol-gels. J Biomed Mater Res 2003; 67: 1276-83.
151. Nablo BJ, Rothrock AR, Schoenfisch MH. Nitric oxide-releasing sol-gels as antibacterial coatings for orthopedic implants. Biomaterials 2005; 26: 917-24.
152. Riccio DA, Coneski PN, Nichols SP, et al. Photoinitiated nitric oxide-releasing tertiary S-nitrosothiol-modified xerogels. ACS Appl Mater Interfaces 2012; 4: 796-804.
153. Halpenny GM, Heilman B, Mascharak PK. Nitric oxide (NO)-induced death of gram-negative bacteria from a light-controlled NO-releasing platform. Chem Biodivers 2012; 9: 1829-39.
154. Hofler L, Koley D, Wu J, et al. Electromodulated release of nitric oxide through polymer material from reservoir of inorganic nitrite salt. RSC Adv 2012; 2: 6765-7.
155. Oh BK, Meyerhoff ME. Spontaneous catalytic generation of nitric oxide from S-nitrosothiols at the surface of polymer films doped with lipophilic copper(II) complex. J Am Chem Soc 2003; 125: 9552-3.
156. Liu K, Meyerhoff ME. Preparation and characterization of an improved Cu2+-cyclen polyurethane material that catalyzes generation of nitric oxide from S-nitrosothiols. J Mater Chem 2012; 22: 18784-7.
157. Torreilles J. Nitric oxide: one of the more conserved and widespread signaling molecules. Front Biosci 2001; 6: 1161-72.
158. Culotta E, Koshland D. NO news is good news. Science 1992; 258: 1862-5.
159. Barnes RJ, Bandi RR, Wong WS, et al. Optimal dosing regimen of nitric oxide donor compounds for the reduction of Pseudomonas aeruginosa biofilm and isolates from wastewater membranes. Biofouling 2013; 29: 203-12.